Implication of low HDL-c levels in patients with average LDL-c levels: A focus on oxidized LDL, large HDL subpopulation, and adiponectin

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Mascarenhas Melo, Filipa ^a   Sereno, José ^a   Teixeira Lemos, Edite ^b   Marado, Daniela ^c   Palavra, Filipe ^a,c   Pinto, Rui ^d   Rocha Pereira, Petronila ^e   Teixeira, Frederico ^a   Reis, Flávio ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; OXYGEN; URIC ACID; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; INFLAMMATION; LIPID METABOLISM; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADIPONECTIN; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LIPID METABOLISM; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXYGEN; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WAIST CIRCUMFERENCE;

EID: 84887385092     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/612038     Document Type: Article

References (64)

1. Keys A., Seven countries: a multivariate analysis of death and coronary heart disease. Annals of Internal Medicine 1980 93 5 786 787
2. Wilson P. W. F., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B., Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 18 1837 1847 2-s2.0-0032510639 (Pubitemid 28213628)
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002 106 25 3143 3121
4. Cannon C. P., Braunwald E., McCabe C. H., Rader D. J., Rouleau J. L., Belder R., Joyal S. V., Hill K. A., Pfeffer M. A., Skene A. M., Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004 350 15 1495 1504 2-s2.0-11144355354 10.1056/NEJMoa040583 (Pubitemid 38477774)
5. LaRosa J. C., Grundy S. M., Waters D. D., Shear C., Barter P., Fruchart J., Gotto A. M., Greten H., Kastelein J. J. P., Shepherd J., Wenger N. K., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005 352 14 1425 1435 2-s2.0-15944410609 10.1056/NEJMoa050461 (Pubitemid 40471450)
6. Pedersen T. R., Faergeman O., Kastelein J. J. P., Olsson A. G., Tikkanen M. J., Holme I., Larsen M. L., Bendiksen F. S., Lindahl C., Szarek M., Tsai J., High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 2005 294 19 2437 2445 2-s2.0-27744603499 10.1001/jama.294.19.2437 (Pubitemid 41627921)
7. de Bacquer D., Dallongeville J., Kotseva K., Cooney M. T., Pajak A., Deckers J. W., Mayer O., Vanuzzo D., Lehto S., Fras Z., Ostor E., Ambrosio G. B., De Backer G., Wood D., Keil U., Sans S., Graham I., Pyörälä K., Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories. International Journal of Cardiology 2012 10.1016/j.ijcard.2012.10.051
8. Mehra S., Movahed H., Movahed A., Emerging therapies for residual risk. Reviews in Cardiovascular Medicine 2012 13 1 24 31
9. Stone N. J., Reducing residual risk in secondary prevention of cardiovascular disease. Circulation 2012 125 16 1958 1960 2-s2.0-84860115121 10.1161/CIRCULATIONAHA.112.101782
10. Fácila L., Núñez J., Sanchis J., Cordero A., Fabregat-Andrés O., Morell S., High-density lipoproteins after acute coronary syndromes: evaluation of residual risk. Revista Española de Cardiología 2013 66 1 65 66
11. Hackam D. G., Anand S. S., Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. Journal of the American Medical Association 2003 290 7 932 940 2-s2.0-0041695231 10.1001/jama.290.7.932 (Pubitemid 37430466)
12. Assmann G., Cullen P., Fruchart J., Greten H., Naruszewicz M., Olsson A., Paoletti R., Riesen W., Stoll M., Tikkanen M., Von Eckardstein A., Implications of emerging risk factors for therapeutic intervention. Nutrition, Metabolism and Cardiovascular Diseases 2005 15 5 373 381 2-s2.0-27644496666 10.1016/j.numecd.2005.06.011 (Pubitemid 41578783)
13. Ishigaki Y., Oka Y., Katagiri H., Circulating oxidized LDL: a biomarker and a pathogenic factor. Current Opinion in Lipidology 2009 20 5 363 369 2-s2.0-73349101401 10.1097/MOL.0b013e32832fa58d
14. Holvoet P., Oxidized LDL and coronary heart disease. Acta Cardiologica 2004 59 5 479 484 2-s2.0-4944232643 10.2143/AC.59.5.2005219 (Pubitemid 39331216)
15. Cziraky M. J., Watson K. E., Talbert R. L., Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Journal of Managed Care Pharmacy 2008 14 8 S3 S28 2-s2.0-56049096263
16. Tekin I. O., Sipahi E. Y., Comert M., Acikgoz S., Yurdakan G., Low-density lipoproteins oxidized after intestinal ischemia/reperfusion in rats. Journal of Surgical Research 2009 157 1 e47 e54 2-s2.0-70349846068 10.1016/j.jss.2008.11.006
17. Kulah E., Tascilar O., Acikgoz S., Karadeniz G., Tekin I. O., Can M., Gun B., Barut F., Comert M., Oxidized LDL accumulation in experimental renal ischemia reperfusion injury model. Renal Failure 2007 29 4 409 415 2-s2.0-34248550995 10.1080/08860220701274975 (Pubitemid 46752338)
18. Tekin N. S., Tekin I. O., Barut F., Sipahi E. Y., Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators of Inflammation 2007 2007 5 2-s2.0-33846694581 10.1155/2007/78454 78454 (Pubitemid 46198130)
19. Bieghs V., Van Gorp P. J., Wouters K., Hendrikx T., Gijbels M. J., van Bilsen M., Bakker J., Binder C. J., Lütjohann D., Staels B., Hofker M. H., Shiri-Sverdlov R., Ldl receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS ONE 2012 7 1 2-s2.0-84856297712 10.1371/journal.pone. 0030668 e30668
20. Bieghs V., van Gorp P. J., Walenbergh S. M., Gijbels M. J., Verheyen F., Buurman W. A., Briles D. E., Hofker M. H., Binder C. J., Shiri-Sverdlov R., Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 2012 56 3 894 903
21. Mertens A. N. N., Holvoet P., Oxidized LDL and HDL: antagonists in atherothrombosis. The FASEB Journal 2001 15 12 2073 2084 2-s2.0-0034804981 10.1096/fj.01-0273rev (Pubitemid 32927925)
22. Nilsson J., Fredrikson G. N., Schiopu A., Shah P. K., Jansson B., Carlsson R., Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Current Pharmaceutical Design 2007 13 10 1021 1030 2-s2.0-34247874714 10.2174/138161207780487557 (Pubitemid 46696558)
23. Hulthe J., Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clinica Chimica Acta 2004 348 1-2 1 8 2-s2.0-4444236665 10.1016/j.cccn.2004.05.021 (Pubitemid 39208994)
24. Brewer H. B. Jr., HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Current Cardiology Reports 2007 9 6 486 492 2-s2.0-36048984001 10.1007/BF02938393 (Pubitemid 350081420)
25. Grover S. A., Kaouache M., Joseph L., Barter P., Davignon J., Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Archives of Internal Medicine 2009 169 19 1775 1780 2-s2.0-70350518673 10.1001/archinternmed.2009.328
26. Nichols G. A., Ambegaonkar B. M., Sazonov V., Brown J. B., Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. American Journal of Cardiology 2009 104 12 1689 1694 2-s2.0-70749137225 10.1016/j.amjcard.2009.07.050
27. Asztalos B. F., Schaefer E. J., HDL in atherosclerosis: actor or bystander? Atherosclerosis 2003 4 1 21 29 2-s2.0-0141672118 10.1016/S1567- 5688(03)00006-0 (Pubitemid 38234504)
28. Hayden M. R., Tyagi S. C., Isolated low high density lipoprotein- cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review. Cardiovascular Diabetology 2005 4, article 1 2-s2.0-13144288971 10.1186/1475-2840-4-1 (Pubitemid 40180232)
29. Asztalos B. F., Roheim P. S., Milani R. L., Lefevre M., McNamara J. R., Horvath K. V., Schaefer E. J., Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 12 2670 2676 2-s2.0-0033670164
30. Pirillo A., Norata G. D., Catapano A. L., High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 2013 124 116 125
31. Assmann G., Nofer J., Atheroprotective effects of high-density lipoproteins. Annual Review of Medicine 2003 54 321 341 2-s2.0-0038798094 10.1146/annurev.med.54.101601.152409 (Pubitemid 37386400)
32. Barter P. J., Nicholls S., Rye K., Anantharamaiah G. M., Navab M., Fogelman A. M., Antiinflammatory properties of HDL. Circulation Research 2004 95 8 764 772 2-s2.0-6344253356 10.1161/01.RES.0000146094.59640.13 (Pubitemid 39390578)
33. Nofer J., Brodde M. F., Kehrel B. E., High-density lipoproteins, platelets and the pathogenesis of atherosclerosis: frontiers in research review: physiological and pathological functions of high-density lipoprotein. Clinical and Experimental Pharmacology and Physiology 2010 37 7 726 735 2-s2.0-77953865873 10.1111/j.1440-1681.2010.05377.x
34. Rodríguez C., González-Díez M., Badimon L., Martínez-González J., Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thrombosis and Haemostasis 2009 101 665 673
35. Schaefer J. R., HDL level or HDL function as the primary target in preventive cardiology. Herz 2012 37 1 51 55 2-s2.0-84857633999 10.1007/s00059-011-3563-z
36. Camont L., Chapman M. J., Kontush A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends in Molecular Medicine 2011 17 10 594 603 2-s2.0-80053574090 10.1016/j.molmed.2011. 05.013
37. Mascarenhas-Melo F., Sereno J., Teixeira-Lemos E., Ribeiro S., Rocha-Pereira P., Cotterill E., Teixeira F., Reis F., Markers of increased cardiovascular risk in postmenopausal women: focus on oxidized-LDL and HDL subpopulations. Disease Markers 2013 35 1 1 12
38. Mascarenhas-Melo F., Marado D., Palavra F., Sereno J., Coelho Á., Pinto R., Teixeira-Lemos E., Teixeira F., Reis F., Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovascular Diabetology 2013 12 61
39. Palavra F., Marado D., Mascarenhas-Melo F., Sereno J., Teixeira-Lemos E., Nunes C. C., Gonçalves G., Teixeira F., Reis F., New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. Disease Markers 2013 34 5 341 348
40. Assmann G., Schulte H., Von Eckardstein A., Huang Y., High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 124 S11 S20 2-s2.0-0029759109 10.1016/0021-9150(96)05852-2 (Pubitemid 26268441)
41. Goldbourt U., Yaari S., Medalie J. H., Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 1 107 113 2-s2.0-0031029838 (Pubitemid 27057331)
42. Eren E., Yilmaz N., Aydin O., High density lipoprotein and it's dysfunction. Open Biochemistry Journal 2012 6 78 93
43. Soran H., Hama S., Yadav R., Durrington P. N., HDL functionality. Current Opinion in Lipidology 2012 23 353 366
44. Mackness M., Durrington P., Mackness B., Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Current Opinion in Lipidology 2004 15 4 399 404 2-s2.0-4043096346 10.1097/01.mol.0000137227.54278. 29 (Pubitemid 39061619)
45. Mackness M. I., Mackness B., Durrington P. N., Paraoxonase and coronary heart disease. Atherosclerosis 2002 3 4 49 55 2-s2.0-0038014076 10.1016/S1567-5688(02)00046-6 (Pubitemid 38234486)
46. Genest J. J., McNamara J. R., Salem D. N., Schaefer E. J., Prevalence of risk factors in men with premature coronary artery disease. American Journal of Cardiology 1991 67 15 1185 1189 2-s2.0-0025731272 10.1016/0002-9149(91)90924-A
47. Genest J. J. Jr., Martin-Munley S. S., McNamara J. R., Ordovas J. M., Jenner J., Myers R. H., Silberman S. R., Wilson P. W. F., Salem D. N., Schaefer E. J., Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992 85 6 2025 2033 2-s2.0-0026762806
48. Woodman R. J., Playford D. A., Watts G. F., Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in type 2 diabetes: associations with blood pressure and HDL cholesterol. Diabetes Research and Clinical Practice 2006 71 1 59 67 2-s2.0-29244432172 10.1016/j.diabres.2005.05.008 (Pubitemid 41821144)
49. Kim N. H., Cho H. J., Kim Y. J., Cho M. J., Choi H. Y., Eun C. R., Kim J., Yang S. J., Yoo H. J., Kim H. Y., Seo J. A., Kim S. G., Baik S. H., Choi D. S., Choi K. M., Combined effect of high-normal blood pressure and low HDL cholesterol on mortality in an elderly Korean population: the South-West Seoul (SWS) study. American Journal of Hypertension 2011 24 8 918 923 2-s2.0-79960557815 10.1038/ajh.2011.78
50. Khan H. A., Alhomida A. S., Sobki S. H., Lipid profile of patients with acute myocardial infarction and its correlation with systemicinflammation. Biomark Insights 2013 8 1 7
51. Popa C. D., Arts E., Fransen J., van Riel P. L., Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators of Inflammation 2012 2012 9 785946 10.1155/2012/785946
52. Lihn A. S., Pedersen S. B., Richelsen B., Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 2005 6 1 13 21 2-s2.0-12444304182 10.1111/j.1467-789X.2005.00159.x
53. Fernandez M. L., Jones J. J., Ackerman D., Barona J., Calle M., Comperatore M. V., Kim J., Andersen C., Leite J. O., Volek J. S., McIntosh M., Kalynych C., Najm W., Lerman R. H., Low HDL cholesterol is associated with increased atherogenic lipoproteins and insulin resistance in women classified with metabolic syndrome. Nutrition Research and Practice 2010 4 6 492 498 2-s2.0-79953269790 10.4162/nrp.2010.4.6.492
54. Wang Z., Nakayama T., Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation 2010 2010 17 2-s2.0-77956869772 10.1155/2010/535918 535918
55. Matsuura E., Hughes G. R. V., Khamashta M. A., Oxidation of LDL and its clinical implication. Autoimmunity Reviews 2008 7 7 558 566 2-s2.0-50949112988 10.1016/j.autrev.2008.04.018
56. Badimon L., Vilahur G., LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Annals of the New York Academy of Sciences 2012 1254 1 18 32 2-s2.0-84859836292 10.1111/j.1749-6632.2012.06480.x
57. García-Heredia A., Marsillach J., Rull A., Triguero I., Fort I., Mackness B., Mackness M., Shih D. M., Joven J., Camps J., Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a nondirected metabolomic study. Mediators of Inflammation 2013 2013 9 156053 10.1155/2013/156053
58. Örem C., Örem A., Uydu H. A., Çelik Ş., Erdöl C., Kural B. V., The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coronary Artery Disease 2002 13 1 65 71 2-s2.0-0036211605 10.1097/00019501-200202000-00009 (Pubitemid 34274252)
59. Kural B. V., Örem C., Uydu H. A., Alver A., Örem A., The effects of lipid-lowering therapy on paraoxonase activities and their relationship with the oxidant-antioxidant system in patients with dyslipidemia. Coronary Artery Disease 2004 15 5 277 283 2-s2.0-4043072119 10.1097/01.mca. 0000135221.32523.a1 (Pubitemid 39061612)
60. Besler C., Heinrich K., Riwanto M., Lüscher T. F., Landmesser U., High-density lipoprotein-mediated anti-atherosclerotic and endothelial- protective effects: a potential novel therapeutic target in cardiovascular disease. Current Pharmaceutical Design 2010 16 13 1480 1493 2-s2.0-77952514390 10.2174/138161210791051013
61. Hill J. M., Zalos G., Halcox J. P. J., Schenke W. H., Waclawiw M. A., Quyyumi A. A., Finkel T., Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. The New England Journal of Medicine 2003 348 7 593 600 2-s2.0-0037434561 10.1056/NEJMoa022287 (Pubitemid 36204953)
62. Degoma E. M., Rader D. J., Novel HDL-directed pharmacotherapeutic strategies. Nature Reviews Cardiology 2011 8 5 266 277 2-s2.0-79955476272 10.1038/nrcardio.2010.200
63. Mahdy K. A., Wonnerth A., Huber K., Wojta J., Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future opportunities. British Journal of Pharmacology 2012 167 6 1177 1194
64. Kypreos K. E., Gkizas S., Rallidis L. S., Karagiannides I., HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochemical Pharmacology 2013 85 11 1575 1578